Health
Candidate monoclonal antibody shows hope as COVID-19 treatment – News-Medical.Net
Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome c…
Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The drug, called CPI-006, targets an immune signaling molecule called CD73 and activates CD73POS B cells, which subsequently promotes antibody production and differentiation into B cells.
In vitro, CPI-006 induce…
-
Noosa News22 hours agoYoung voices shape Sunshine Coast’s future
-
Business21 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News21 hours agoQueensland government to review greenhouse gas emission reduction targets
-
Noosa News21 hours agoSXSW Sydney Has Announced the First 40 Speakers That’ll Be Taking to the Stage at Its 2025 Conference